drugset / Trial / NCT04233658

Cynara Scolymus Extract for Treatment of Diabetes Mellitus Type 2

NCT04233658 ↗

Phase 3 Unknown 20 enrolled Stefan Fischli
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Edible parts of the artichoke plant (Cynara cardunculus, Cynara scolymus) are traditionally known in folk-medicine for lipid lowering and choleretic effects. Furthermore, antidiabetic effects are described. In the past year's research attributed health promoting effects to the main active compounds chlorogenic acid, luteolin and apigenin. Present literature indicates potential antidiabetic effects by different mechanisms like downregulation of gluconeogenesis, increased GLP-1 secretion and modification of insulin signalling. Up to now only few human clinical trials provide insufficient data to conclude the therapeutic potential of cynara scolymus extract in the treatment of type 2 diabetes. The primary objective is to evaluate the antidiabetic effect and the mechanisms of glucose lowering by a 12-week treatment with a highly-standardized extract of cynara scolymus in subjects with diabetes mellitus type 2 compared to placebo.

Timeline

Start
2020-05
Primary completion
2022-05
Completion
2022-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cynara Scolymus Traditional medicine (herbal / TCM) — —